查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929580

GalNAc遞送技術市場依治療領域、臨床階段、作用機制及最終使用者分類，全球預測，2026-2032年

GalNAc Delivery Technology Market by Therapeutic Area, Clinical Stage, Mechanism Of Action, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年 Galnac 輸送技術市值為 5.5237 億美元，預計到 2026 年將成長至 5.9921 億美元，預計到 2032 年將達到 9.1012 億美元，複合年成長率為 7.39%。

關鍵市場統計數據
基準年 2025 5.5237億美元
預計年份：2026年 5.9921億美元
預測年份 2032 9.1012億美元
複合年成長率 (%) 7.39%

基於 GalNAc 的肝細胞靶向 RNA 療法的基本科學原理、轉化里程碑及其對產業和醫療相關人員的戰略意義

GalNAc介導的遞送代表了寡核苷酸療法在高效肝細胞靶向給藥方面的一項突破。透過利用N-乙醯半乳糖胺配體與去Glico受體的高親和性結合，研發人員在肝臟標靶治療計畫中實現了更高的藥物攝取效率和治療指數。本文闡述了RNA療法生態系統中相關技術原理、近期轉化里程碑以及對研發人員、投資者和臨床相關人員的策略意義。

科學創新、監管政策的明確性以及策略合作的整合，推動了基於 GalNAc 的療法和商業化途徑的成熟生態系統。

在科學、監管和商業性因素的共同推動下，GalNAc遞送技術正經歷著一場變革性的轉變。偶聯化學和連接子設計的進步提高了有效載荷的柔軟性，為支持超越傳統RNA干擾的多種作用機制奠定了基礎。因此，研發人員正在探索將GalNAc與新一代寡核苷酸化學相結合的聯合療法，以增強治療效果的持久性和標靶選擇性。這項科學進步正在重塑候選藥物的優先排序，並開拓了先前被認為超出肝臟標靶治療範圍的適應症。

預計2025年前後關稅政策發展和貿易政策措施對寡核苷酸計畫供應鏈、籌資策略和區域製造決策的影響

2025 年前公佈的貿易政策和關稅正對支持寡核苷酸和偶聯物生產的全球供應鏈施加巨大壓力。影響原料、某些類別的實驗室設備和中間體化學品供應的關稅正在推高到岸成本，使供應商選擇更加複雜，並促使企業重新評估其庫存和籌資策略。為此，研發人員和契約製造正擴大考慮近岸外包和供應商多元化，以此來降低跨境關稅波動帶來的風險。

結合治療領域、臨床開發階段、作用機制和最終用戶優先順序的深度細分分析，為您的 GalNAc 計畫揭示客製化的發展路徑。

我們基於細分市場的 GalNAc 遞送領域分析，結合治療領域、臨床階段、作用機制和最終用戶，揭示了其中蘊含的許多機會。按治療領域分類，該領域涵蓋心血管疾病（細分為動脈粥樣硬化和血脂異常症）、肝臟疾病（細分為乙型肝炎和非酒精性脂肪性肝炎）、代謝性疾病（細分為遺傳性高膽固醇症和原發性高草酸尿症）以及腫瘤學（重點關注肝細胞癌）。這些針對特定適應症的路徑驅動著不同的標靶檢驗策略、生物標記選擇和終點指標，進而影響臨床試驗設計和商業化計畫。

區域發展、製造和商業化趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的戰略選擇。

區域趨勢將對基於 GalNAc 的療法的研發、生產和商業化產生重大影響，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。美洲的生態系統得益於密集的生物技術叢集、創業投資管道以及支持快速臨床開發的完善法規結構。這些優勢促進了早期創新和夥伴關係協議的達成，從而加速轉化研究並主導全球專案。

觀察到的企業策略和產能投資表明，平台整合、專注於生物技術創新和 CRO（受託研究機構）擴張，這些共同加速了 GalNAc 療法的開發。

GalNAc遞送領域主要企業的活動展現出多元化的策略態勢，涵蓋了從專注於平台型規模化生產的公司到針對特定適應症的專業研發公司。現有製藥公司正透過收購和策略聯盟整合自身能力，以獲取後期研發資產和生產技術。這些措施反映出其致力於降低研發管線風險，並收購可整合到多個治療領域的成熟遞送平台。

為開發者提供的實用策略建議：整合科學差異化、供應鏈韌性和市場進入規劃，以加速 GalNAc 專案的成功

為了充分利用 GalNAc 遞送技術的機遇，產業領導者應採取多維策略，整合科學差異化、供應鏈韌性和市場進入準備。首先，應優先投資於連接子化學和有效載荷最佳化，以提高靶向特異性並最大限度地減少脫靶效應。這些技術差異化將是確保臨床優勢和吸引合作夥伴的關鍵。同時，應儘早調整分析開發和品質體系，以確保製程驗證能夠隨著臨床開發進展和監管要求而擴展。

結合專家訪談、文獻綜合和情境分析的透明且可複製的調查方法將為 GalNAc相關人員產生可操作的見解。

本研究整合了一手和二手訊息，旨在建構對 GalNAc 遞送領域的全面視角。一級資訊來源包括與藥物發現、轉化開發、生產製造和商業策略等領域的專家進行的結構化訪談和檢驗討論。基於這些討論，我們對平台優勢、開發瓶頸以及主要參與者的競爭地位進行了定性評估。此外，調查方法還納入了對同行評審科學文獻、監管指導文件和公開資訊的系統性回顧，以確保研究結果的可驗證性和檢驗性。

一項全面的技術、監管和商業計劃，旨在將 GalNAc 的潛力轉化為持續的臨床和市場影響。

總之，GalNAc遞送技術代表了一種穩健且日益檢驗的肝臟定向RNA療法途徑，其應用範圍涵蓋心血管、肝臟、代謝和腫瘤等多個領域。偶聯化學和有效載荷相容性方面的科學進步提高了多種療法的治療指數，而監管政策的明確和戰略夥伴關係則促進了高效的臨床應用。同時，關稅驅動的供應鏈重組和區域製造地轉移等外部壓力凸顯了積極主動的產業計畫的必要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. GalNAc遞送技術市場（依治療領域分類）

  • 心血管疾病
    • 動脈粥狀硬化
    • 血脂異常症
  • 肝病
    • B型肝炎
    • 非酒精性脂肪性肝炎
  • 代謝性疾病
    • 遺傳性高膽固醇症
    • 原發性草酸尿症
  • 腫瘤學

9. GalNAc遞送技術市場（依臨床階段分類）

  • 商業的
  • 第一/二期
    • 第一階段
    • 第二階段
  • 第三階段
  • 臨床前

10. GalNAc遞送技術市場依作用機制分類

  • 反義寡核苷酸
    • 嗎啉代寡核苷酸
    • 硫代磷酸酯
  • 基因編輯
    • CRISPR-Cas9
    • 塔倫
  • mRNA療法
    • 治療性mRNA
    • 疫苗mRNA
  • RNA干擾
    • ShRNA
    • siRNA

11. GalNAc遞送技術市場（依最終用戶分類）

  • 學術機構
  • 生技公司
  • CRO（受託研究機構）
  • 製藥公司

12. GalNAc遞送技術市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. GalNAc遞送技術市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國 GalNAc 遞送技術市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國 GalNAc 遞送技術市場

第16章：中國 GalNAc 遞送技術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Beam Therapeutics Inc.
  • BioNTech SE
  • CRISPR Therapeutics AG
  • CureVac NV
  • Editas Medicine, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Development Center Americas, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A380695182F

The GalNAc Delivery Technology Market was valued at USD 552.37 million in 2025 and is projected to grow to USD 599.21 million in 2026, with a CAGR of 7.39%, reaching USD 910.12 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 552.37 million
Estimated Year [2026] USD 599.21 million
Forecast Year [2032] USD 910.12 million
CAGR (%) 7.39%

Foundational scientific principles, translational milestones, and strategic implications of GalNAc-enabled hepatocyte-targeted RNA therapeutics for stakeholders across industry and medicine

GalNAc-mediated delivery has become a defining advance in the efficient hepatocyte-targeted administration of oligonucleotide therapeutics. By leveraging the high-affinity binding of N-acetylgalactosamine ligands to asialoglycoprotein receptors, developers have achieved improved uptake and therapeutic index in liver-directed programs. This introduction establishes the technological principles, recent translational milestones, and the strategic implications for developers, investors, and clinical stakeholders who are positioning themselves in the RNA therapeutics ecosystem.

Across the scientific continuum, GalNAc conjugation has enabled lower dose requirements, reduced systemic exposure, and clearer pharmacodynamic relationships for a range of modalities including small interfering RNA and antisense oligonucleotides. Consequently, recent clinical entries and late-stage programs illustrate how target biology and linker chemistry interplay to define both efficacy and safety. Transitioning from bench to bedside, program teams must weigh manufacturing complexity, regulatory expectations for oligonucleotide quality attributes, and the evolving real-world evidence base that will ultimately drive adoption in diverse therapeutic areas.

This section sets the stage for deeper analysis by highlighting the platform's core strengths-target specificity, scalable conjugation chemistries, and growing clinical validation-while also signposting the persistent challenges that require strategic mitigation. Those challenges include optimizing payload stability, navigating intellectual property landscapes, and aligning commercial models with payer and provider expectations for novel gene-silencing therapies. With that context, the subsequent sections examine structural shifts in the competitive landscape, regulatory and trade influences, and actionable recommendations for industry leaders.

Converging scientific innovations, regulatory clarifications, and strategic collaborations driving a matured ecosystem for GalNAc-enabled therapeutics and commercialization pathways

The GalNAc delivery landscape is undergoing transformative shifts driven by converging scientific, regulatory, and commercial forces. Advances in conjugation chemistry and linker design have increased payload flexibility, enabling the platform to support diverse mechanisms of action beyond classical RNA interference. As a result, developers are pairing GalNAc with next-generation oligonucleotide chemistries and exploring combination approaches that amplify therapeutic durability and target selectivity. This scientific progress is reshaping candidate prioritization and opening indications previously considered out of scope for liver-directed strategies.

Concurrently, regulatory pathways are adapting to the specificities of oligonucleotide therapeutics, with agencies issuing guidance that clarifies expectations for impurity control, pharmacokinetic bridging, and post-market safety monitoring. These regulatory clarifications reduce uncertainty for sponsors but also elevate the bar for manufacturing controls and analytical validation. In parallel, industry alliances and public-private partnerships have intensified, enabling shared access to specialized manufacturing capabilities and bolstering translational throughput.

Market dynamics are shifting as larger pharmaceutical companies increasingly collaborate with or acquire biotech firms possessing proprietary GalNAc-enabled assets, accelerating commercialization timelines. At the same time, capital formation has become more outcome-driven, prioritizing programs with clear biomarkers and tolerability profiles that demonstrate durable target engagement. Taken together, these shifts are producing a more mature ecosystem in which scientific innovation, regulatory harmonization, and commercial strategy co-evolve to de-risk late-stage development and support broader clinical adoption.

How tariff dynamics and trade policy measures scheduled around 2025 are reshaping supply chains, procurement strategies, and regional manufacturing decisions for oligonucleotide programs

Trade policy and tariff measures announced in the run-up to 2025 are exerting measurable pressure on global supply chains that support oligonucleotide and conjugate manufacturing. Tariff actions affecting raw materials, certain laboratory equipment classes, and intermediate chemical inputs can increase landed costs, complicate supplier selection, and prompt firms to re-evaluate their inventory and sourcing strategies. In response, developers and contract manufacturers are increasingly assessing nearshoring and supplier diversification as mechanisms to reduce exposure to cross-border tariff volatility.

Beyond direct cost effects, tariffs can catalyze longer lead times and administrative burdens related to customs classifications and compliance documentation. These operational frictions have downstream consequences for clinical timelines when clinical supply manufacturing slots become more contested. Consequently, strategic procurement planning now routinely incorporates tariff sensitivity analyses and scenario-based supply-chain modeling to preserve program momentum.

Importantly, the cumulative impact of tariffs is not limited to cost inflation. Tariff-induced shifts in supplier geography can reshape regional clustering of capabilities, potentially accelerating capacity build-out in areas with preferential trade conditions. As a result, partnerships with contract research and manufacturing organizations are being renegotiated to include clauses that address tariff pass-through, contingency supply, and collaborative inventory management. For industry leaders, the practical implication is a need to integrate trade-policy foresight into clinical stage planning, capital allocation, and outsourcing strategies to maintain resilience against 2025-era tariff dynamics.

Deep segmentation insights that combine therapeutic focus, clinical development stage, mechanistic modality, and end user priorities to reveal tailored pathways for GalNAc program advancement

Segmentation-based analysis of the GalNAc delivery space reveals nuanced opportunity zones when therapeutic area, clinical stage, mechanism of action, and end user are considered in combination. Based on therapeutic area, the landscape spans cardiovascular diseases-subdivided into atherosclerosis and dyslipidemia-liver diseases-subdivided into hepatitis B and nonalcoholic steatohepatitis-metabolic disorders-subdivided into familial hypercholesterolemia and primary hyperoxaluria-and oncology with a focus on hepatocellular carcinoma. These indication-specific pathways drive distinct target validation strategies, biomarker selection, and endpoints that influence both clinical design and commercialization planning.

In terms of clinical stage segmentation, the market encompasses commercial assets, Phase I/II programs that further bifurcate into Phase I and Phase II trials, Phase III candidates, and preclinical research. Differences across these stages affect investor risk appetites, partner interest, and the technical requirements for manufacturing scale-up. Early-stage programs prioritize target engagement assays and delivery optimization, while later stage assets require robust process validation, long-term safety data, and market-access planning.

For mechanism of action, GalNAc-enabled platforms are being deployed across antisense oligonucleotides-further classified into morpholino and phosphorothioate chemistries-gene editing modalities such as Crispr Cas9 and Talen, mRNA therapies distinguished between therapeutic mRNA and vaccine mRNA, and RNA interference approaches including shRNA and siRNA. Each modality imposes distinct constraints on payload size, stability, and formulation, which in turn determine analytic strategies and regulatory dossiers. Finally, consideration of end users-academic institutions, biotechnology firms, contract research organizations, and pharmaceutical companies-illuminates differing priorities: academic groups tend to emphasize exploratory science and translational proof-of-concept, biotech firms focus on de-risking and partnering, CROs concentrate on operational execution, and pharmaceutical companies emphasize late-stage validation and commercialization readiness. Understanding these intersecting segmentations enables stakeholders to align capabilities and investments with the most relevant pathways to clinical and commercial success.

Regionally differentiated development, manufacturing, and commercialization dynamics shaping strategic choices across the Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics significantly influence the development, manufacturing, and commercial deployment of GalNAc-enabled therapeutics, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, ecosystem strength derives from dense biotech clusters, access to venture capital, and established regulatory frameworks that support rapid clinical advancement. These attributes favor early-stage innovation and partnership deals that accelerate translational work and global program leadership.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and targeted public funding have encouraged formation of centers of excellence in oligonucleotide chemistry and clinical trial networks. These regional collaborations can shorten recruitment timelines for specific hepatology and metabolic indications and support multicenter Phase II and Phase III studies. In addition, manufacturers in the region are investing in analytical capabilities that align with increasingly stringent quality expectations.

The Asia-Pacific region has emerged as a pivotal hub for both clinical development and manufacturing scale-up. Strong government support for biotechnology, competitive manufacturing costs, and growing domestic markets make the region an attractive locus for late-stage production and commercial launch strategies. Moreover, patient populations with high disease prevalence for certain liver and metabolic disorders create compelling opportunities for localized clinical studies. Taken together, regional strategies must balance regulatory pathways, clinical trial feasibility, intellectual property considerations, and supply-chain logistics to optimize program outcomes in each geography.

Observed corporate strategies and capability investments indicating platform consolidation, biotech innovation focus, and CRO expansion that collectively accelerate GalNAc therapeutic development

Key company behaviors in the GalNAc delivery arena reveal a spectrum of strategic postures from platform-centric scale-ups to indication-focused specialist developers. Established pharmaceutical companies are consolidating capabilities through acquisitions and strategic alliances that secure late-stage assets and manufacturing know-how. These moves reflect an emphasis on de-risking pipelines and acquiring validated delivery platforms that can be integrated across multiple therapeutic franchises.

Biotechnology firms continue to drive innovation at the chemistry and payload levels, advancing proprietary linker technologies, novel conjugation strategies, and bespoke oligonucleotide sequences. Smaller firms often pursue partnering strategies with larger organizations to access commercialization infrastructure, while simultaneously protecting high-value intellectual property through sophisticated patent portfolios and defensive filings. Contract research and manufacturing organizations are expanding capacity and quality systems to serve the specialized needs of oligonucleotide developers, investing in analytics, sterile fill-finish capabilities, and supply-chain management tools.

Academic institutions and translational centers remain critical sources of discovery-stage innovation and early clinical proof-of-concept. These organizations frequently collaborate with industry partners to move promising GalNAc-enabled therapies into human studies. Across the competitive landscape, successful companies combine deep scientific expertise with operational rigor and market-focused development plans. They also demonstrate an ability to navigate regulatory expectations proactively, align with payer evidence needs, and structure partnerships that accelerate time to key inflection points.

Actionable strategic recommendations for developers to integrate scientific differentiation, supply-chain resilience, and market-access planning to accelerate GalNAc program success

Industry leaders should adopt a multi-dimensional strategy that integrates scientific differentiation, supply-chain resilience, and market-access readiness to capitalize on GalNAc delivery opportunities. First, prioritize investments in linker chemistry and payload optimization that enhance target specificity while minimizing off-target effects; these technical differentiators will be key to securing clinical advantage and partner interest. Concurrently, align analytical development and quality systems early so that process validation scales with clinical progression and regulatory expectations.

Second, incorporate trade-policy and tariff scenario planning into procurement and outsourcing decisions. Establish contractual flexibility with suppliers and CROs to mitigate cost pass-through and to secure continuity of supply. Consider geographic diversification of manufacturing and the use of regional hubs to reduce exposure to single points of failure. Third, design clinical programs with clear biomarker-driven endpoints and adaptive elements that permit efficient de-risking; this approach attracts capital and enhances negotiating leverage with potential commercial partners.

Finally, craft commercial and market-access strategies that articulate the value proposition in terms payers and providers recognize-durable clinical benefit, reduced treatment burden, and demonstrable improvements in key health-economic metrics. Engage early with regulatory and HTA stakeholders to align evidence generation with reimbursement requirements. By executing on these recommendations, developers can convert technological promise into sustained clinical and commercial outcomes.

Transparent, reproducible research methodology combining expert interviews, literature synthesis, and scenario analysis to produce actionable insights for GalNAc stakeholders

This research synthesizes primary and secondary intelligence to construct a robust view of the GalNAc delivery landscape. Primary inputs include structured interviews and validation discussions with subject matter experts across discovery, translational development, manufacturing, and commercial strategy. These conversations informed qualitative assessments of platform strengths, development bottlenecks, and the competitive positioning of leading organizations. In addition, the methodology incorporated a systematic review of peer-reviewed scientific literature, regulatory guidance documents, and public disclosures to ground findings in verifiable evidence.

Analytical methods involved cross-sectional comparison across therapeutic areas and clinical stages, triangulating mechanistic differences with operational requirements. Scenario analysis and sensitivity frameworks were applied to examine the potential impacts of trade-policy shifts and supply-chain disruptions. Validation steps included iterative expert debriefs and internal consistency checks to ensure conclusions were defensible and actionable. Where uncertainty remains, the report flags open questions and suggests targeted research priorities to reduce decision risk.

Overall, the research methodology emphasizes transparency in data sources, reproducibility in analytic approaches, and practical relevance for decision-makers seeking to deploy resources effectively. Supplemental appendices document interview protocols, literature inclusion criteria, and a glossary of technical terms to support interpretability for cross-functional teams.

Synthesis and forward-looking perspective emphasizing integrated technical, regulatory, and commercial planning to translate GalNAc promise into durable clinical and market impact

In conclusion, GalNAc delivery represents a robust and increasingly validated pathway to liver-directed RNA therapeutics, with implications that extend across cardiovascular, hepatic, metabolic, and oncologic indications. Scientific advances in conjugation chemistry and payload compatibility have improved the therapeutic index for a variety of modalities, while regulatory clarifications and strategic partnerships are facilitating efficient clinical translation. At the same time, external pressures such as tariff-driven supply-chain reconfiguration and regional manufacturing shifts underscore the need for proactive operational planning.

For stakeholders, the path forward requires an integrated approach that aligns technical development with regulatory, commercial, and procurement strategies. Those who invest early in differentiating chemistries, resilient supply chains, and evidence frameworks suitable for payer dialogue will be best positioned to convert clinical promise into sustainable patient impact. The landscape will continue to evolve as new modalities emerge and as policy and market forces reshape incentive structures, making continuous monitoring and adaptive planning essential for long-term success.

Taken together, the synthesis presented here equips decision-makers with the contextual understanding needed to prioritize initiatives, select partners, and structure investments that accelerate the development of safe, effective, and commercially viable GalNAc-enabled therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GalNAc Delivery Technology Market, by Therapeutic Area

  • 8.1. Cardiovascular Diseases
    • 8.1.1. Atherosclerosis
    • 8.1.2. Dyslipidemia
  • 8.2. Liver Diseases
    • 8.2.1. Hepatitis B
    • 8.2.2. Non Alcoholic Steatohepatitis
  • 8.3. Metabolic Disorders
    • 8.3.1. Familial Hypercholesterolemia
    • 8.3.2. Primary Hyperoxaluria
  • 8.4. Oncology

9. GalNAc Delivery Technology Market, by Clinical Stage

  • 9.1. Commercial
  • 9.2. Phase I/II
    • 9.2.1. Phase I
    • 9.2.2. Phase II
  • 9.3. Phase III
  • 9.4. Preclinical

10. GalNAc Delivery Technology Market, by Mechanism Of Action

  • 10.1. Antisense Oligonucleotides
    • 10.1.1. Morpholino
    • 10.1.2. Phosphorothioate
  • 10.2. Gene Editing
    • 10.2.1. Crispr Cas9
    • 10.2.2. Talen
  • 10.3. Mrna Therapies
    • 10.3.1. Therapeutic Mrna
    • 10.3.2. Vaccine Mrna
  • 10.4. Rna Interference
    • 10.4.1. ShRNA
    • 10.4.2. SiRNA

11. GalNAc Delivery Technology Market, by End User

  • 11.1. Academic Institutions
  • 11.2. Biotechnology Firms
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. GalNAc Delivery Technology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. GalNAc Delivery Technology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. GalNAc Delivery Technology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States GalNAc Delivery Technology Market

16. China GalNAc Delivery Technology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Akcea Therapeutics, Inc.
  • 17.6. Alnylam Pharmaceuticals, Inc.
  • 17.7. Arcturus Therapeutics Holdings Inc.
  • 17.8. Arrowhead Pharmaceuticals, Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Bayer AG
  • 17.11. Beam Therapeutics Inc.
  • 17.12. BioNTech SE
  • 17.13. CRISPR Therapeutics AG
  • 17.14. CureVac N.V.
  • 17.15. Editas Medicine, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Ionis Pharmaceuticals, Inc.
  • 17.18. Moderna, Inc.
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc.
  • 17.21. Pfizer Inc.
  • 17.22. Regeneron Pharmaceuticals, Inc.
  • 17.23. Roche Holding AG
  • 17.24. Sanofi S.A.
  • 17.25. Sarepta Therapeutics, Inc.
  • 17.26. Takeda Development Center Americas, Inc.
  • 17.27. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY DYSLIPIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY NON ALCOHOLIC STEATOHEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRIMARY HYPEROXALURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MORPHOLINO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHOSPHOROTHIOATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CRISPR CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY VACCINE MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SHRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 236. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 238. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 239. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 270. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 272. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 273. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 275. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 276. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 277. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 278. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 283. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 288. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 289. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 290. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 291. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY RNA INTERFERENCE, 2018-2032 (USD MILLION)
  • TABLE 293. NATO GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY LIVER DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY PHASE I/II, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES GALNAC DELIVERY TECHNOLOGY MARKET SIZE, BY MRNA THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES GAL